Skip to main content
Premium Trial:

Request an Annual Quote

Cepheid s Q2 Revenues Grow 90 Percent on Strong Reagent Sales; Loss Stays Flat

NEW YORK, Aug. 5 (GenomeWeb News) - Cepheid yesterday reported a steep increase in revenues along with flat losses for the second quarter of 2005.

 

The company had $21.4 million in revenues, up 89 percent from last year's $11.3 million during the same quarter. Most of this increase resulted from sales of reagents and disposables, which increased almost fourfold.

 

Research and developments costs climbed to $4.5 million from 3.9 million during the year-ago period.

 

Cepheid reported a net loss of $3.6 million, or $.09 per share, similar to last year's $3.7 million, or $.09 per share, for the same quarter.

 

As of June 30, Cepheid had $18.4 million in cash and cash equivalents, and $34 million in marketable securities.

The Scan

Transcriptomic, Epigenetic Study Appears to Explain Anti-Viral Effects of TB Vaccine

Researchers report in Science Advances on an interferon signature and long-term shifts in monocyte cell DNA methylation in Bacille Calmette-Guérin-vaccinated infant samples.

DNA Storage Method Taps Into Gene Editing Technology

With a dual-plasmid system informed by gene editing, researchers re-wrote DNA sequences in E. coli to store Charles Dickens prose over hundreds of generations, as they recount in Science Advances.

Researchers Model Microbiome Dynamics in Effort to Understand Chronic Human Conditions

Investigators demonstrate in PLOS Computational Biology a computational method for following microbiome dynamics in the absence of longitudinally collected samples.

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.